AZN.UK

10,390

-0.23%↓

GSK

1,411

-0.04%↓

INDV

1,112

+4.51%↑

AZN.UK

10,390

-0.23%↓

GSK

1,411

-0.04%↓

INDV

1,112

+4.51%↑

AZN.UK

10,390

-0.23%↓

GSK

1,411

-0.04%↓

INDV

1,112

+4.51%↑

AZN.UK

10,390

-0.23%↓

GSK

1,411

-0.04%↓

INDV

1,112

+4.51%↑

AZN.UK

10,390

-0.23%↓

GSK

1,411

-0.04%↓

INDV

1,112

+4.51%↑

Search

PureTech Health Plc

Fermé

126.2 0.16

Résumé

Variation du prix de l'action

24h

Actuel

Min

122.8

Max

126.6

Chiffres clés

By Trading Economics

Revenu

70M

Ventes

4M

P/E

Moyenne du Secteur

8.013

50.291

Marge bénéficiaire

1,727.216

Employés

56

EBITDA

102M

Dividendes

By Dow Jones

Prochains Résultats

27 août 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

308M

Ouverture précédente

126.04

Clôture précédente

126.2

PureTech Health Plc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

1 juil. 2025, 23:09 UTC

Résultats

Constellation Brands 1Q Profit, Sales Decline Amid Softer Consumer Demand -- Update

1 juil. 2025, 19:16 UTC

Acquisitions, Fusions, Rachats

Sabadell Seeks Shareholder Approval of Nearly $4 Billion Sale of U.K. Unit to Santander

1 juil. 2025, 23:47 UTC

Market Talk

Nikkei May Fall Amid U.S. Tariff Uncertainty -- Market Talk

1 juil. 2025, 23:41 UTC

Market Talk

Gold Steady, Underpinned by U.S. Fiscal-Deficit Concerns -- Market Talk

1 juil. 2025, 22:23 UTC

Acquisitions, Fusions, Rachats

James Hardie: Deal Represents Implied Value of $8.4 Billion

1 juil. 2025, 22:23 UTC

Acquisitions, Fusions, Rachats

James Hardie: Cash and Stock Deal Implies $54.18 Per AZEK Share

1 juil. 2025, 22:21 UTC

Acquisitions, Fusions, Rachats

James Hardie Completes Acquisition of AZEK

1 juil. 2025, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

1 juil. 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

1 juil. 2025, 20:24 UTC

Résultats

Constellation Brands Earnings Miss as Consumers Cool on Alcohol -- Barrons.com

1 juil. 2025, 19:55 UTC

Market Talk

Oil Futures Resume Cautious Rally -- Market Talk

1 juil. 2025, 19:27 UTC

Market Talk

U.S. Natural Gas Futures Lose More Ground -- Market Talk

1 juil. 2025, 19:12 UTC

Market Talk

Dollar Little Changed as Tax-And-Spending Bill Advances -- Market Talk

1 juil. 2025, 19:01 UTC

Acquisitions, Fusions, Rachats

Sabadell Seeks Shareholder Approval of Nearly $4B Sale of U.K. Unit to Santander

1 juil. 2025, 18:41 UTC

Acquisitions, Fusions, Rachats

How DexCom, Insulet, and Amedisys Might Be Affected by Medicare Cuts -- Barrons.com

1 juil. 2025, 18:33 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

1 juil. 2025, 18:33 UTC

Market Talk

Gold Gains as Investors Look Ahead on Budget Bill -- Market Talk

1 juil. 2025, 18:32 UTC

Market Talk

Mexico Manufacturing PMIs Remain Weak in June -- Market Talk

1 juil. 2025, 18:22 UTC

Market Talk

Remittances to Mexico Down in May -- Market Talk

1 juil. 2025, 17:45 UTC

Market Talk

Seasonal Demand Supports Further Oil Gains -- Market Talk

1 juil. 2025, 17:01 UTC

Acquisitions, Fusions, Rachats

Danone Completed Acquisition of Majority Stake in Kate Farms

1 juil. 2025, 16:55 UTC

Résultats

10 European Dividend Stocks That Could Beat Their U.S. Counterparts -- Barrons.com

1 juil. 2025, 16:27 UTC

Market Talk

Trade Concerns Ease in Bank of Mexico Survey -- Market Talk

1 juil. 2025, 16:25 UTC

Market Talk
Acquisitions, Fusions, Rachats

Home Depot's GMS Buy Unlocks New Vertical Adjacent to SRS -- Market Talk

1 juil. 2025, 16:20 UTC

Market Talk

Health Care Roundup: Market Talk

1 juil. 2025, 15:48 UTC

Market Talk
Acquisitions, Fusions, Rachats

Home Depot's Offer for GMS Unlikely to Be Beat -- Market Talk

1 juil. 2025, 15:46 UTC

Market Talk

Global Equities Roundup: Market Talk

1 juil. 2025, 15:46 UTC

Market Talk

Amazon Seen With Improved Logistics Ahead of Longer Prime Day -- Market Talk

1 juil. 2025, 14:54 UTC

Market Talk

Thales Expected to Stick to This Year's Sales Guidance -- Market Talk

1 juil. 2025, 14:49 UTC

Market Talk

Platinum Prices Extend Rally on China Demand, Supply Worries -- Market Talk

Comparaison

Variation de prix

PureTech Health Plc prévision

Note du Consensus

By TipRanks

0 ratings

0

Achat

0

Maintien

0

Vente

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos PureTech Health Plc

PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies. It also develops SPT-300, an oral drug of allopregnanolone for the treatment of anxious depression; SPT-320, a novel prodrug of agomelatine for the treatment of generalized anxiety disorder; and SPT-348, a prodrug of a non-hallucinogenic neuroplastogen for the treatment of mood and other neuropsychiatric disorders. In addition, the company is developing hydrogels to enable the oral administration of peptide therapeutics in preclinical development. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.